

Antonio Addis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7642323/publications.pdf>

Version: 2024-02-01

98
papers

3,677
citations

185998

28
h-index

133063

59
g-index

125
all docs

125
docs citations

125
times ranked

3731
citing authors

#	ARTICLE	IF	CITATIONS
1	Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies. <i>BMJ: British Medical Journal</i> , 1998, 317, 839-843.	2.4	280
2	Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: Evidence from a meta-analysis. <i>Clinical Therapeutics</i> , 2002, 24, 302-316.	1.1	246
3	Adverse effects of prenatal methimazole exposure. <i>Teratology</i> , 2001, 64, 262-266.	1.8	217
4	Pregnancy Outcome Following Gestational Exposure to Venlafaxine: A Multicenter Prospective Controlled Study. <i>American Journal of Psychiatry</i> , 2001, 158, 1728-1730.	4.0	217
5	Pregnancy Outcome Following Gestational Exposure to Fluoroquinolones: a Multicenter Prospective Controlled Study. <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 1336-1339.	1.4	214
6	Impact of Body Mass Index and Obesity on Clinical Response to Systemic Treatment for Psoriasis. <i>Dermatology</i> , 2008, 217, 365-373.	0.9	199
7	Integrated care pathways for airway diseases (AIRWAYS-ICPs). <i>European Respiratory Journal</i> , 2014, 44, 304-323.	3.1	154
8	Fetal effects of cocaine: an updated meta-analysis. <i>Reproductive Toxicology</i> , 2001, 15, 341-369.	1.3	153
9	A Multicentre Prospective Controlled Study to Determine the Safety of Trazodone and Nefazodone Use during Pregnancy. <i>Canadian Journal of Psychiatry</i> , 2003, 48, 106-110.	0.9	109
10	Prenatal exposure to misoprostol and vascular disruption defects: A case-control study. <i>American Journal of Medical Genetics Part A</i> , 2000, 95, 302-306.	2.4	107
11	Risk Classification Systems for Drug Use During Pregnancy. <i>Drug Safety</i> , 2000, 23, 245-253.	1.4	104
12	Safety of fluoxetine during the first trimester of pregnancy: a meta-analytical review of epidemiological studies. <i>Psychological Medicine</i> , 2000, 30, 89-94.	2.7	103
13	International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines. <i>Vaccine</i> , 2013, 31, 4448-4458.	1.7	91
14	A Prospective Controlled Multicentre Study of Clarithromycin in Pregnancy. <i>American Journal of Perinatology</i> , 1998, 15, 523-525.	0.6	87
15	Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey. <i>Intensive Care Medicine</i> , 2007, 33, 426-434.	3.9	82
16	Risk of serious infections, cutaneous bacterial infections, and granulomatous infections in patients with psoriasis treated with anti-tumor necrosis factor agents versus classic therapies: Prospective meta-analysis of Psonet registries. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 299-308.e16.	0.6	75
17	Fetal safety of loratadine use in the first trimester of pregnancy: A multicenter study. <i>Journal of Allergy and Clinical Immunology</i> , 2003, 111, 479-483.	1.5	71
18	High vitamin A intake in early pregnancy and major malformations: A multicenter prospective controlled study. <i>Teratology</i> , 1999, 59, 7-11.	1.8	70

#	ARTICLE	IF	CITATIONS
19	The safety of omeprazole during pregnancy: A multicenter prospective controlled study. American Journal of Obstetrics and Gynecology, 1998, 179, 727-730.	0.7	67
20	Metoclopramide for Nausea and Vomiting of Pregnancy: A Prospective Multicenter International Study. American Journal of Perinatology, 2002, 19, 311-316.	0.6	65
21	Toward estimating the impact of changes in immigrants' insurance eligibility on hospital expenditures for uncompensated care. BMC Health Services Research, 2003, 3, 1.	0.9	60
22	Prospective, Controlled, Multicentre Study of Loperimide in Pregnancy. Canadian Journal of Gastroenterology & Hepatology, 2000, 14, 185-187.	1.8	56
23	Meta-analytic review of the clinical effectiveness of oral deferiprone (L 1). European Journal of Clinical Pharmacology, 1999, 55, 1-6.	0.8	50
24	AIRWAYS-ICPs (European Innovation Partnership on Active and Healthy Ageing) from concept to implementation. European Respiratory Journal, 2016, 47, 1028-1033.	3.1	50
25	Fetal Effects of Metoclopramide Therapy for Nausea and Vomiting of Pregnancy. New England Journal of Medicine, 2000, 343, 445-446.	13.9	44
26	Pharmacoeconomic Analysis of Venlafaxine in the Treatment of Major Depressive Disorder. Pharmacoeconomics, 1997, 12, 286-296.	1.7	35
27	Quality Assessment of Pharmacoeconomic Abstracts of Original Research Articles in Selected Journals. Annals of Pharmacotherapy, 1997, 31, 423-428.	0.9	33
28	Pregnancy outcome after gestational exposure to terfenadine: A multicenter, prospective controlled study. Journal of Allergy and Clinical Immunology, 1999, 104, 953-956.	1.5	29
29	Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 245-253.	1.3	29
30	Cisapride use during human pregnancy: a prospective, controlled multicenter study. Digestive Diseases and Sciences, 1997, 42, 1848-1852.	1.1	25
31	Quality Assessment of Economic Evaluations Published in Pharmacoeconomics. Pharmacoeconomics, 1997, 12, 685-694.	1.7	24
32	Role of healthcare databases and registries for surveillance of orphan drugs in the real-world setting: the Italian case study. Expert Opinion on Drug Safety, 2019, 18, 497-509.	1.0	24
33	Inequalities in access to biological treatments for psoriasis: results from the Italian Psocare registry. British Journal of Dermatology, 2017, 176, 1331-1338.	1.4	23
34	New approaches to analysing prescription data and to transfer pharmacoepidemiological and evidence-based reports to prescribers. Pharmacoepidemiology and Drug Safety, 2002, 11, 721-726.	0.9	22
35	Comparative effectiveness and safety of erythropoiesis-stimulating agents (biosimilars vs originators) in clinical practice: a population-based cohort study in Italy. BMJ Open, 2017, 7, e011637.	0.8	22
36	The Italian Horizon Scanning Project. European Journal of Clinical Pharmacology, 2009, 65, 775-781.	0.8	20

#	ARTICLE	IF	CITATIONS
37	Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study. <i>Drug Safety</i> , 2019, 42, 1437-1447.	1.4	19
38	Using GRADE methodology to assess innovation of new medicinal products in Italy. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 93-105.	1.1	18
39	Pattern of Use of Biosimilar and Originator Somatropin in Italy: A Population-Based Multiple Databases Study During the Years 2009-2014. <i>Frontiers in Endocrinology</i> , 2018, 9, 95.	1.5	17
40	Anticancer drug prices and clinical outcomes: a cross-sectional study in Italy. <i>BMJ Open</i> , 2019, 9, e033728.	0.8	17
41	Direct and Indirect Impact of COVID-19 for Patients with Immune-Mediated Inflammatory Diseases: A Retrospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2388.	1.0	17
42	Clinical evidence continuous medical education: a randomised educational trial of an open access e-learning program for transferring evidence-based information - ICEKUBE (Italian Clinical Evidence) Tj ETQq0 0 OugBT /Overdlock 10 T		
43	The pharmacovigilance program on natalizumab in Italy: 2Âyears of experience. <i>Neurological Sciences</i> , 2009, 30, 163-165.	0.9	16
44	Impact of Guidance on the Prescription Patterns of G-CSFs for the Prevention of Febrile Neutropenia Following Anticancer Chemotherapy: A Population-Based Utilization Study in the Lazio Region. <i>BioDrugs</i> , 2017, 31, 117-124.	2.2	16
45	Large-Scale Postmarketing Surveillance of Biological Drugs for Immune-Mediated Inflammatory Diseases Through an Italian Distributed Multi-Database Healthcare Network: The VALORE Project. <i>BioDrugs</i> , 2021, 35, 749-764.	2.2	16
46	Current National Initiatives About Drug Policies and Cost Control in Europe. <i>Journal of Ambulatory Care Management</i> , 2004, 27, 127-131.	0.5	15
47	Comparative efficacy and safety in ESA biosimilars vs. originators in adults with chronic kidney disease: a systematic review and meta-analysis. <i>Journal of Nephrology</i> , 2018, 31, 321-332.	0.9	15
48	Drug Use in Pregnancy and Lactation: the Work of a Regional Drug Information Center. <i>Annals of Pharmacotherapy</i> , 1995, 29, 632-633.	0.9	14
49	The Italian reference sites of the European innovation partnership on active and healthy ageing: Progetto Mattone Internazionale as an enabling factor. <i>Annali Dell'Istituto Superiore Di Sanita</i> , 2017, 53, 60-69.	0.2	13
50	Population-based cohort study on comparative effectiveness and safety of biologics in inflammatory bowel disease. <i>Clinical Epidemiology</i> , 2018, Volume 10, 203-213.	1.5	12
51	Promoting Better Clinical Trials and Drug Information as Public Health Interventions for the COVID-19 Emergency in Italy. <i>Annals of Internal Medicine</i> , 2020, 173, 654-655.	2.0	12
52	Comparative Effectiveness of Pharmacological Interventions for Covid-19: A Systematic Review and Network Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2021, 12, 649472.	1.6	11
53	Clinical Evidence: a useful tool for promoting evidence-based practice?. <i>BMC Health Services Research</i> , 2003, 3, 24.	0.9	10
54	Using Clinical Evidence in a National Continuing Medical Education Program in Italy. <i>PLoS Medicine</i> , 2007, 4, e113.	3.9	10

#	ARTICLE	IF	CITATIONS
55	Natalizumab: a country-based surveillance program. <i>Neurological Sciences</i> , 2008, 29, 235-237.	0.9	10
56	Healthcare Database Networks for Drug Regulatory Policies: International Workshop on the Canadian, US and Spanish Experience and Future Steps for Italy. <i>Drug Safety</i> , 2020, 43, 1-5.	1.4	10
57	European Clinical Trials Directive: the Italian position. <i>Lancet, The</i> , 2004, 363, 1651-1652.	6.3	9
58	Patients' charges in Slovakia. <i>Lancet, The</i> , 2004, 363, 1651.	6.3	9
59	Decrease in [3H]hemicholinium binding to high-affinity choline uptake sites in deafferented striatum: restoration by oxiracetam. <i>Brain Research</i> , 1990, 530, 156-160.	1.1	8
60	Drug use during pregnancy. <i>Lancet, The</i> , 2001, 357, 800.	6.3	8
61	Neonatal outcomes following new reimbursement limitations on palivizumab in Italy. <i>Archives of Disease in Childhood</i> , 2018, 103, 1163-1167.	1.0	8
62	Drug use during pregnancy. <i>Lancet, The</i> , 2001, 357, 800.	6.3	7
63	Can systematic reviews contribute to regulatory decisions?. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 507-509.	0.8	7
64	Acid-suppressing drugs during pregnancy. <i>Canadian Family Physician</i> , 1997, 43, 1923-4, 1927.	0.1	7
65	Drug Prescriptions in the Outpatient Management of COVID-19: Evidence-Based Recommendations Versus Real Practice. <i>Frontiers in Pharmacology</i> , 2022, 13, 825479.	1.6	7
66	Folic acid: a public-health challenge. <i>Lancet, The</i> , 2006, 367, 2057.	6.3	6
67	Drug discontinuation in pregnant women with psoriasis: The PSO â€•MOTHER cohort study. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 904-912.	0.9	5
68	A Nutritional Approach to the Prevention of Cancer: from Assessment to Personalized Intervention. <i>Translational Medicine @ UniSa</i> , 2015, 13, 33-41.	0.8	5
69	Orphan Drug Prices and Epidemiology of Rare Diseases: A Cross-Sectional Study in Italy in the Years 2014â€•2019. <i>Frontiers in Medicine</i> , 2022, 9, 820757.	1.2	5
70	New drug treatment for asthma: Clinical versus statistical significance. <i>Journal of Pediatrics</i> , 2002, 140, 484.	0.9	4
71	Real world data to identify target population for new CARâ€•T therapies. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 78-85.	0.9	4
72	Folic Acid for the Prevention of Neural Tube Defects. <i>JAMA Pediatrics</i> , 2017, 171, 709.	3.3	3

#	ARTICLE	IF	CITATIONS
73	How Do Drug Regulatory Bodies Deal With Potential Innovative Therapies?. Therapeutic Innovation and Regulatory Science, 2020, 54, 195-199.	0.8	3
74	Informing women about drugs they take during pregnancy: promoting consumers' drug information as integral part of care. , 1998, 20, 236-237.		2
75	Use of nimesulide in children. Lancet, The, 1999, 354, 1034.	6.3	2
76	Studies on drug switchability showed heterogeneity in methodological approaches: a scoping review. Journal of Clinical Epidemiology, 2018, 101, 5-16.	2.4	2
77	Workshop on the Italian Pharmacovigilance System in the International Context: Critical Issues and Perspectives. Drug Safety, 2019, 42, 683-687.	1.4	2
78	In Search of Predictors of Switching Between Erythropoiesis-Stimulating Agents in Clinical Practice: A Multi-Regional Cohort Study. BioDrugs, 2020, 34, 55-64.	2.2	2
79	Determinants of first-line biological treatment in patients with rheumatoid arthritis. Medicine (United States), 2021, 100, e25943.	0.4	2
80	Safety and effectiveness of direct oral anticoagulants versus vitamin K antagonists: results from 3 Italian regions. Recenti Progressi in Medicina, 2019, 110, 195-202.	0.8	2
81	Information needs on precision medicine: a survey of Italian health care professionals. Annali Dell'Istituto Superiore Di Sanita, 2018, 54, 316-323.	0.2	2
82	Vitamin A supplementation during pregnancy in developed countries. Lancet, The, 1995, 345, 736-737.	6.3	1
83	Palivizumab reimbursement criteria and neonatal RSV hospitalisation: a regional retrospective review. BMJ Paediatrics Open, 2021, 5, e000985.	0.6	1
84	Price and reimbursement for orphan medicines and managed entry agreements: does Italy need a framework?. Global & Regional Health Technology Assessment, 0, 8, 114-119.	0.2	1
85	How Do Drug Regulatory Bodies Deal With Potential Innovative Therapies?. Therapeutic Innovation and Regulatory Science, 0, , 216847901882088.	0.8	1
86	Tuberculosis during pregnancy. Canadian Family Physician, 1996, 42, 1461-2.	0.1	1
87	Therapeutic approach to hypertension during pregnancy. Canadian Family Physician, 1998, 44, 1245-7.	0.1	1
88	The Italian Network for Monitoring Medication Use During Pregnancy (MoM-Net): Experience and Perspectives. Frontiers in Pharmacology, 2021, 12, 699062.	1.6	1
89	Lasciate ogni speranza voi che non sperimentate: il Recovery collaborative group e il Recovery fund. Medico E Bambino, 2020, 39, 551-552.	0.1	1
90	Response to the letter by Williams et al.. Intensive Care Medicine, 2007, 33, 1490-1491.	3.9	0

#	ARTICLE	IF	CITATIONS
91	Drotrecogin alfa (activated) in severe sepsis. Lancet Infectious Diseases, The, 2013, 13, 107-108.	4.6	0
92	Qual � il Giusto Place in Therapy Dell'olmesartan?. Global & Regional Health Technology Assessment, 2017, 4, grhta.5000264.	0.2	0
93	The Standard of Care Definitions on COVID-19 Pharmacological Clinical Trials: A Systematic Review. Frontiers in Pharmacology, 2021, 12, 749514.	1.6	0
94	Adverse Effects of Prenatal Methimazole Exposure. Obstetrical and Gynecological Survey, 2002, 57, 336-337.	0.2	0
95	Biosimilar formulations of gonadotropins in a central Italian region: use patterns and time trends. European Journal of Public Health, 2020, 30, .	0.1	0
96	Asthma during pregnancy. Canadian Family Physician, 1997, 43, 1717-8.	0.1	0
97	Determinants of use of gonadotropin formulations to treat female infertility in an Italian region. European Journal of Public Health, 2020, 30, .	0.1	0
98	Your cardiac patient wants to become a mother. Risk considerations and advice Part I–your cardiac patient asks advice on a possible pregnancy. Italian Heart Journal: Official Journal of the Italian Federation of Cardiology, 2000, 1, 605-12.	0.1	0